NeoPharm CO., LTD.

KOSDAQ:A092730 株式レポート

時価総額:₩229.9b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

NeoPharm バランスシートの健全性

財務の健全性 基準チェック /66

NeoPharmの総株主資本は₩160.3B 、総負債は₩0.0で、負債比率は0%となります。総資産と総負債はそれぞれ₩183.4Bと₩23.1Bです。 NeoPharmの EBIT は₩25.1Bで、利息カバレッジ比率-5.8です。現金および短期投資は₩113.0Bです。

主要情報

0%

負債資本比率

₩0

負債

インタレスト・カバレッジ・レシオ-5.8x
現金₩113.01b
エクイティ₩160.25b
負債合計₩23.10b
総資産₩183.35b

財務の健全性に関する最新情報

Recent updates

NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Jun 13
NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price

Apr 24
Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price

NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Mar 25
NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Mar 28
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Mar 15
What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

Mar 02
How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

We're Watching These Trends At NeoPharm (KOSDAQ:092730)

Feb 18
We're Watching These Trends At NeoPharm (KOSDAQ:092730)

We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

Feb 08
We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

Jan 26
NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Jan 15
An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

Jan 04
Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Dec 24
NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Dec 15
What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Dec 04
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

Nov 23
Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

財務状況分析

短期負債: A092730の 短期資産 ( ₩140.3B ) が 短期負債 ( ₩22.6B ) を超えています。

長期負債: A092730の短期資産 ( ₩140.3B ) が 長期負債 ( ₩471.6M ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: A092730は負債がありません。

負債の削減: A092730負債比率が0.7%であった 5 年前と比べて負債がありません。

債務返済能力: A092730には負債がないため、営業キャッシュフロー でカバーする必要はありません。

インタレストカバレッジ: A092730には負債がないため、利息支払い の負担は問題になりません。


貸借対照表


健全な企業の発掘